MBC-11

• Description :

  MBC-11 is a first-in-class conjugate of the bone-targeting bisphosphonate etidronate covalently linked to the antimetabolite cytarabine (araC) . MBC-11 has the potential for tumor-induced bone disease (TIBD) research[1].

• UNSPSC :

  12352005

• Target :

  Apoptosis

• Type :

  Reference compound

• Related Pathways :

  Apoptosis

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/MBC-11.html

• Solubility :

  10 mM in DMSO

• Smiles :

  CC(P(O)(O)=O)(P(O)(OP(O)(OC[C@@H]1[C@@H](O)[C@H](O)[C@H](N2C=CC(N)=NC2=O)O1)=O)=O)O

• Molecular Formula :

  C11H20N3O14P3

• Molecular Weight :

  511.21

• References & Citations :

  [1]Reinholz MM, et al. A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites. Bone. 2010 Jul;47 (1) :12-22.|[2]Zinnen SP, et al. First-in-Human Phase I Study of MBC-11, a Novel Bone-Targeted Cytarabine-Etidronate Conjugate in Patients with Cancer-Induced Bone Disease. Oncologist. 2019 Mar;24 (3) :303-e102.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• CAS Number :

  [332863-86-2]